SCHEMBL240089

SCHEMBL240089

CC(C)(C)c1ccc(-n2c(-c3ccc(B4OC(C)(C)C(C)(C)O4)cc3)ccc2-c2ccc(B3OC(C)(C)C(C)(C)O3)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 13/20 0.46
LPL P06858 12/20 0.46
HIF1A Q16665 1/20 0.37
F11 P03951 2/20 0.37
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 2/20 0.35
CA12 O43570 1/20 0.35
CA3 P07451 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA7 P43166 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CA5B Q9Y2D0 1/20 0.35
MDM2 Q00987 1/20 0.33
F2 P00734 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20707082 0.89 LIPG (0.37) LIPGLPLHIF1AF11MDM2
SCHEMBL12684488 0.89 LPL (0.37) LIPGLPLHIF1AF11
SCHEMBL12524043 0.83 LIPG (0.65) LIPGLPLHIF1AF11CA1
SCHEMBL417710 0.82 LPL (0.55) LIPGLPLHIF1AF11CA1
SCHEMBL12687307 0.79 TSHR (0.33) PTGS2
SCHEMBL12103672 0.78 LPL (0.40) LIPGLPLHIF1AF11CA1
SCHEMBL12938319 0.77 LPL (0.51) LIPGLPLHIF1ACA1CA2
SCHEMBL14315730 0.76 HIF1A (0.40) LIPGLPLHIF1ACA1CA2
SCHEMBL1983558 0.76 HIF1A (0.42) LIPGLPLHIF1AF11CA1
SCHEMBL240619 0.76 LIPG (0.41) LIPGLPLHIF1AF11CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 US disclosed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 US disclosed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 US disclosed
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 EP disclosed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 US disclosed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 US disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 US disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 US disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 US disclosed
US-10028937-B2 Anti-viral compounds ABBVIE INC. (US) 2018-07-24 US disclosed
US-20120004196-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-01-05 US disclosed
EP-2368890-A1 Hepatitis C virus inhibitors Abbott Laboratories (US) 2011-09-28 EP disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 US disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 US disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 US disclosed
EP-2337781-A2 ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION Abbott Laboratories (US) 2011-06-29 EP disclosed
US-20110092415-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-04-21 US disclosed
US-20110092415-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-04-21 US disclosed
US-20110092415-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-04-21 US disclosed
WO-2010144646-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028937-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS LIPG 768/4885LPL 1419/4885HIF1A 1619/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LIPG 768/4885LPL 1419/4885HIF1A 1619/4885
US-20110092415-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LIPG 768/4885LPL 1419/4885HIF1A 1619/4885
US-20110207699-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LIPG 768/4885LPL 1419/4885HIF1A 1619/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LIPG 768/4885LPL 1419/4885HIF1A 1619/4885
US-20120004196-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LIPG 768/4885LPL 1419/4885HIF1A 1619/4885
US-10039754-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS LIPG 768/4885LPL 1419/4885HIF1A 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.